CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0001695: Cardiac arrestHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug705 Modified Rankin score Wiki 0.71
drug1063 Standard of Care (Intravenous access) Wiki 0.71
drug725 NIO® (Intraosseous access) Wiki 0.71
drug247 Cardiopulmonary resuscitation Wiki 0.71

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D006323 Heart Arrest NIH 1.00
D004630 Emergencies NIH 0.25

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting

The current COVID-19 pandemic, this is especially since the transmission of SARS-CoV-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients COVID-19 disease may be asymptomatic. As recommended by the CDC medical personnel should be equipped with full personal protective equipment (PPE) for AGP in contact with suspected/confirmed COVID-19 patient. Therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.

NCT04366947 Emergency Medicine Cardiopulmonary Arrest Shock Device: NIO® (Intraosseous access) Device: Standard of Care (Intravenous access)
MeSH:Heart Arrest Emergencies
HPO:Cardiac arrest Cardiorespiratory arrest

Primary Outcomes

Description: successful placement of intravascular device

Measure: Success rate of first intravascular access attempt

Time: 1 day

Secondary Outcomes

Description: time to successful access

Measure: time to successful access

Time: 1 day

Description: number of attempts to successful access

Measure: number of attempts to successful access

Time: 1 day

Description: time to therapy including but not limited to time to fluids, antibiotics, and antiarrythmics

Measure: time to infusion

Time: 1 day

Description: complication rates

Measure: complication rates

Time: 1 day

Description: the rate of survival to hospital admission

Measure: ROSC

Time: 1 day

2 Cardiac Arrest Incidence and Outcome Among Patient With COVID-19 Pneumonia in French ICUs

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic. Among COVID-19 complications, in-hospital cardiac arrest (IHCA) was reported with a very poor outcome in a retrospective single-center study (0,7% of 30 days survival with good neurological outcome among IHCA patients with a resuscitation attempt), related to its natural course and management. The incidence of unexpected in-ICU cardiac arrest (ICUCA) due to COVID-19 is still unknown. Additionally, outcome of COVID-19 patients admitted in ICU for an out-of-hospital cardiac arrest (OHCA) is also undescribed. The objective this study is : - to report the incidence of ICUCA among patients hospitalized in French ICU for COVID-19. - to report morbidity and mortality among COVID-19 patients admitted alive in ICU for an OHCA or an IHCA. The secondary objective is to assess outcome and identify risk factors of ICUCA occurrence among patients admitted for COVID-19.

NCT04373759 Sars-CoV2 Covid-19 Other: Cardiopulmonary resuscitation Other: Modified Rankin score
MeSH:Heart Arrest
HPO:Cardiac arrest Cardiorespiratory arrest

Primary Outcomes

Description: Percentage of unexpected in-intensive care unit cardiac arrest among COVID-19 patients admitted to intensive care unit

Measure: Incidence of unexpected cardiac arrest

Time: 7 months

Secondary Outcomes

Description: Diabetes, hypertension, smoking, dyslipidemia, coronary artery disease, chronic respiratory insufficiency, chronic heart failure, chronic renal insufficiency, chronic hepatic insufficiency, chronic neurological disease, cancer, malignant hemopathy. Charlson score's minimum and maximum values are 0 and 40 respectively, the lowest score corresponds to a better outcome.

Measure: Charlson score

Time: 7 months

Description: Respiratory failure, neurological impairment, circulatory failure, hepatic failure, haematological failure, renal failure. Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcome

Measure: Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest

Time: 7 months

Description: Cardiac origin; Respiratory origin; Metabolic origin; unknown origin

Measure: Etiology retained to explain cardiac arrest occurrence

Time: 7 months

Description: 0 - no symptoms at all - no significant disability despite symptoms; able to carry out all usual duties and activities - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance - Moderate disability; requiring some help, but able to walk without assistance - Moderately severe disability; unable to walk and attend to bodily needs without assistance - Severe disability; bedridden, incontinent and requiring constant nursing care and attention - Dead

Measure: Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months

Time: 3 months

HPO Nodes